203 related articles for article (PubMed ID: 25139024)
21. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.
Wang H; Zhang SY; Wang S; Lu J; Wu W; Weng L; Chen D; Zhang Y; Lu Z; Yang J; Chen Y; Zhang X; Chen X; Xi C; Lu D; Zhao S
Neuro Oncol; 2009 Dec; 11(6):790-802. PubMed ID: 19289490
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204.
Zhou H; Ma Y; Zhong D; Yang L
Biomed Pharmacother; 2019 Apr; 112():108633. PubMed ID: 30784927
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1.
Sun JY; Xiao WZ; Wang F; Wang YQ; Zhu YH; Wu YF; Miao ZL; Lin YC
Mol Med Rep; 2015 Aug; 12(2):2355-9. PubMed ID: 25901521
[TBL] [Abstract][Full Text] [Related]
24. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells.
Rani SB; Rathod SS; Karthik S; Kaur N; Muzumdar D; Shiras AS
Neuro Oncol; 2013 Oct; 15(10):1302-16. PubMed ID: 23814265
[TBL] [Abstract][Full Text] [Related]
25. Expression level of human miR-34a correlates with glioma grade and prognosis.
Gao H; Zhao H; Xiang W
J Neurooncol; 2013 Jun; 113(2):221-8. PubMed ID: 23529798
[TBL] [Abstract][Full Text] [Related]
26. Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.
Vera J; Schmitz U; Lai X; Engelmann D; Khan FM; Wolkenhauer O; Pützer BM
Cancer Res; 2013 Jun; 73(12):3511-24. PubMed ID: 23447575
[TBL] [Abstract][Full Text] [Related]
27. FER1L4/miR-372/E2F1 works as a ceRNA system to regulate the proliferation and cell cycle of glioma cells.
Xia L; Nie D; Wang G; Sun C; Chen G
J Cell Mol Med; 2019 May; 23(5):3224-3233. PubMed ID: 30887657
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA SNHG16 contributes to glioma malignancy by competitively binding miR-20a-5p with E2F1.
Yang BY; Meng Q; Sun Y; Gao L; Yang JX
J Biol Regul Homeost Agents; 2018; 32(2):251-261. PubMed ID: 29685003
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1.
Tu Y; Gao X; Li G; Fu H; Cui D; Liu H; Jin W; Zhang Y
Cancer Res; 2013 Oct; 73(19):6046-55. PubMed ID: 23950210
[TBL] [Abstract][Full Text] [Related]
30. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
Guo M; Jiang Z; Zhang X; Lu D; Ha AD; Sun J; Du W; Wu Z; Hu L; Khadarian K; Shen J; Lin Z
Carcinogenesis; 2014 Aug; 35(8):1698-706. PubMed ID: 24480809
[TBL] [Abstract][Full Text] [Related]
31. The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma.
Chen L; Zhang W; Yan W; Han L; Zhang K; Shi Z; Zhang J; Wang Y; Li Y; Yu S; Pu P; Jiang C; Jiang T; Kang C
Carcinogenesis; 2012 Nov; 33(11):2276-82. PubMed ID: 22871495
[TBL] [Abstract][Full Text] [Related]
32. E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.
Sang XB; Zong ZH; Wang LL; Wu DD; Chen S; Liu BL; Zhao Y
Oncotarget; 2017 Feb; 8(9):14777-14793. PubMed ID: 28146423
[TBL] [Abstract][Full Text] [Related]
33. Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro.
Guo YF; Wang XB; Tian XY; Li Y; Li B; Huang Q; Zhang M; Li Z
World J Surg Oncol; 2012 Jun; 10():128. PubMed ID: 22741575
[TBL] [Abstract][Full Text] [Related]
34. PPARα, a predictor of patient survival in glioma, inhibits cell growth through the E2F1/miR-19a feedback loop.
Shi Y; Tao T; Liu N; Luan W; Qian J; Li R; Hu Q; Wei Y; Zhang J; You Y
Oncotarget; 2016 Dec; 7(51):84623-84633. PubMed ID: 27835866
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance.
Yang W; Wei J; Guo T; Shen Y; Liu F
Exp Cell Res; 2014 Aug; 326(1):22-35. PubMed ID: 24930954
[TBL] [Abstract][Full Text] [Related]
36. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.
Zhang L; Pickard K; Jenei V; Bullock MD; Bruce A; Mitter R; Kelly G; Paraskeva C; Strefford J; Primrose J; Thomas GJ; Packham G; Mirnezami AH
Cancer Res; 2013 Nov; 73(21):6435-47. PubMed ID: 23950211
[TBL] [Abstract][Full Text] [Related]
37. PDGF Engages an E2F-USP1 Signaling Pathway to Support ID2-Mediated Survival of Proneural Glioma Cells.
Rahme GJ; Zhang Z; Young AL; Cheng C; Bivona EJ; Fiering SN; Hitoshi Y; Israel MA
Cancer Res; 2016 May; 76(10):2964-76. PubMed ID: 26951930
[TBL] [Abstract][Full Text] [Related]
38. miR-135a promotes gastric cancer progression and resistance to oxaliplatin.
Yan LH; Chen ZN; Li-Li ; Chen J; Wei WE; Mo XW; Qin YZ; Lin Y; Chen JS
Oncotarget; 2016 Oct; 7(43):70699-70714. PubMed ID: 27683111
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
40. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
Li H; Yu L; Liu J; Bian X; Shi C; Sun C; Zhou X; Wen Y; Hua D; Zhao S; Ren L; An T; Luo W; Wang Q; Yu S
Oncotarget; 2017 Mar; 8(12):19723-19737. PubMed ID: 28160566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
